X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4038) 4038
Newsletter (700) 700
Newspaper Article (680) 680
Publication (193) 193
Book Review (83) 83
Magazine Article (67) 67
Trade Publication Article (65) 65
Book Chapter (9) 9
Web Resource (6) 6
Data Set (5) 5
Dissertation (4) 4
Conference Proceeding (3) 3
Paper (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multiple sclerosis (3489) 3489
humans (2721) 2721
interferon (2030) 2030
interferon beta-1a (1966) 1966
clinical neurology (1440) 1440
female (1425) 1425
index medicus (1360) 1360
male (1309) 1309
adult (1302) 1302
interferon-beta - therapeutic use (1219) 1219
interferon beta (1094) 1094
multiple sclerosis - drug therapy (1009) 1009
biological response modifiers (975) 975
middle aged (897) 897
double-blind (772) 772
interferon beta-1b (764) 764
multiple sclerosis, relapsing-remitting - drug therapy (753) 753
neurosciences (708) 708
treatment outcome (681) 681
care and treatment (589) 589
research (586) 586
glatiramer acetate (571) 571
neurology (571) 571
magnetic resonance imaging (558) 558
drug therapy (548) 548
adjuvants, immunologic - therapeutic use (526) 526
placebo-controlled trial (523) 523
clinical trials (475) 475
interferon-beta - administration & dosage (457) 457
disease progression (434) 434
patients (434) 434
therapy (398) 398
disability (394) 394
interferon-beta - adverse effects (394) 394
interferon-beta (392) 392
medical research (348) 348
multicenter (340) 340
immunologic factors - therapeutic use (337) 337
immunology (336) 336
pharmacology & pharmacy (334) 334
studies (334) 334
adolescent (332) 332
disease (332) 332
pharmaceutical industry (330) 330
viral antigens (298) 298
multiple sclerosis - immunology (296) 296
immunosuppressive agents - therapeutic use (289) 289
disability evaluation (286) 286
natalizumab (286) 286
medicine, experimental (280) 280
multiple sclerosis - therapy (270) 270
recurrence (269) 269
medicine, general & internal (267) 267
young adult (263) 263
adjuvants, immunologic - administration & dosage (251) 251
multiple-sclerosis (242) 242
animals (241) 241
analysis (238) 238
follow-up studies (234) 234
mri (232) 232
time factors (232) 232
health aspects (222) 222
multiple sclerosis - diagnosis (221) 221
interferon-beta - pharmacology (219) 219
peptides - therapeutic use (216) 216
multiple sclerosis - pathology (209) 209
adjuvants, immunologic - adverse effects (208) 208
medicine (208) 208
neutralizing antibodies (207) 207
brain - pathology (206) 206
reports (201) 201
biological products industry (198) 198
dosage and administration (196) 196
efficacy (195) 195
multiple sclerosis - physiopathology (192) 192
psychiatry (192) 192
nuclear magnetic resonance--nmr (191) 191
aged (190) 190
drugs (190) 190
medicine & public health (190) 190
double-blind method (186) 186
follow-up (181) 181
research article (178) 178
risk factors (178) 178
clinical trials as topic (176) 176
prospective studies (173) 173
interferon-beta - immunology (170) 170
injections, subcutaneous (169) 169
retrospective studies (169) 169
drug dosages (165) 165
inflammation (165) 165
cytokines (164) 164
dose-response relationship, drug (164) 164
multiple sclerosis, relapsing-remitting - immunology (162) 162
development and progression (161) 161
diagnostic-criteria (161) 161
trial (159) 159
autoimmune diseases (154) 154
drug administration schedule (150) 150
randomized controlled trials as topic (146) 146
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5309) 5309
German (79) 79
French (46) 46
Spanish (39) 39
Russian (33) 33
Japanese (14) 14
Polish (11) 11
Czech (8) 8
Hungarian (8) 8
Portuguese (6) 6
Chinese (4) 4
Croatian (2) 2
Dutch (1) 1
Italian (1) 1
Korean (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 3, pp. 221 - 234
Journal Article
Journal Article
by Panitch, H and Anaissie, E and Cines, D and DeGroot, L and Dorsey, F and Phillips, T and Simon, J and Brinar, V and Demarin, V and Janculjak, D and Rudez, J and Vladic, A and Czlonkowska, A and Mirowska-Guzel, D and Kozubski, W and Kwiecinski, H and Stelmasiak, Z and Szczudlik, A and Boyko, A and Gusev, EI and Skoromets, A and Stolyarov, I and Yakhno, N and Zavalishin, I and Shawcross, J and Jones, J and Cox, A.L and Bass, A and Wenzel, D and Biton, V and Cascione, M and Cleeremans, B and Cooper, J and Coyle, P.K and Madigan, D and Cutler, B and Fox, E.J and Mayer, L and Tyer, R and Gazda, S and Glyman, S and Gupta, A and Harney, J and Hutton, G and Jacobs, D and Khan, O and Lisak, R and Tselis, A and Klapper, J and Liss, J and Meyer, D and Rae-Grant, A and Rossman, H and Boudouris, W and Belkin, M and Pierce, R and Royal, W and Shubin, R and Sider, D and Stein, M and Steingo, B and Sullivan, H and Twyman, C and Webb, R and Weinshenker, B and Keegan, B.M and Rauchwarter, D and Wingerchuk, D and Carter, J and Wray, S and Wynn, D and Allen, N and Nagar, C and O'Brien, D and Paskavitz, J and Schaefer, P and Valente, W and Beardsley, D and Bussel, J and Goldberg, M and MacMillan, R and Scadden, D and D'Agostino, R.B and Pencina, M and Gonzales, G and Waldmann, H and Hale, G and Coles, Alasdair J and Compston, D. Alastair S and Selmaj, Krzysztof W and Lake, Stephen L and Moran, Susan and Margolin, David H and Norris, Kim and Tandon, P.K and The CAMMS223 Trial Investigators and CAMMS223 Trial Investigators
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 17, pp. 1786 - 1801
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2016, Volume 82, Issue 2, pp. 380 - 388
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2006, Volume 354, Issue 9, pp. 911 - 923
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2014, Volume 13, Issue 7, pp. 657 - 665
Summary Background Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less... 
Neurology | Clinical trials | Multiple sclerosis | Biological response modifiers | Viral antigens | Interferon beta | Pain | Influenza | Interferon | Infections | Drug therapy | Drug dosages | Engineering Sciences
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 6/2012, Volume 52, Issue 6, pp. 798 - 808
This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple... 
polyethylene glycol | pharmacokinetics and drug metabolism | biomarkers | multiple sclerosis | pharmacodynamics | NEUTRALIZING ANTIBODIES | EFFICACY | VOLUNTEERS | MARKERS | ADHERENCE | DELIVERY | THERAPY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | COMPARATIVE PHARMACOKINETICS | 2',5'-Oligoadenylate Synthetase - blood | Humans | Middle Aged | Interferons - adverse effects | Half-Life | Polyethylene Glycols - adverse effects | Male | RNA, Messenger - metabolism | Dose-Response Relationship, Drug | T-Lymphocytes, Helper-Inducer - drug effects | Young Adult | Immunosuppressive Agents - blood | Interferon-beta - adverse effects | Interferons - blood | Biotransformation | Injections, Subcutaneous | Adult | Female | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Polyethylene Glycols - pharmacology | 2',5'-Oligoadenylate Synthetase - metabolism | Interferon-beta - administration & dosage | Interferon-beta - chemistry | T-Lymphocytes, Helper-Inducer - metabolism | Double-Blind Method | Interferons - pharmacology | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Injections, Intramuscular | Neopterin - blood | Polyethylene Glycols - administration & dosage | 2',5'-Oligoadenylate Synthetase - genetics | Gene Expression Regulation - drug effects | Interferons - administration & dosage | RNA, Messenger - blood | Interferon-beta - pharmacology | Adolescent | Immunosuppressive Agents - adverse effects | Usage | Pharmacology | Health aspects | Sclerosis | Multiple sclerosis | Pharmacodynamics | Helper cells | Data processing | Leukocytes (neutrophilic) | Lymphocytes T | Gene expression | neopterin | Lymphocytes | alpha -Interferon | Interferon | Pharmacokinetics
Journal Article